Core Insights - Elanco has experienced a strong start in 2026, building on momentum from Q4 2025 with a reported 9% growth in the quarter [1] - The company's innovation basket has exceeded expectations, generating $892 million for the year [1] - All four quadrants of the business have performed well, contributing to better-than-expected cash flow and allowing for additional debt repayment [1] - The company ended the year with a leverage ratio of 3.6x and has maintained momentum into 2026 [1] - Guidance for the year aligns with targets set during the Investor Day [1]

Core Insights - Hikma achieved significant growth in 2025, launching 84 products and becoming the largest pharmaceutical company in MENA by sales for the first time in its history [1] - The company is focusing on strengthening its injectable business and has begun implementing leadership changes to address challenges [1] Business Performance - The Branded division is recognized as a best-in-class operation in MENA, characterized by local market expertise, a broad portfolio, and strong customer relationships [2] - Hikma Rx has gained importance, focusing on growth in higher-value areas such as complex medicines and CMO services [2] Market Position - Hikma Rx is positioned as one of the leading U.S. domestic producers of generic medicines, contributing positively to the U.S. healthcare landscape [3] - The injectable segment maintains strong margins, but continued investment is necessary to sustain growth [3]

Core Insights - Barrett Business Services, Inc. (BBSI) reported a 5% increase in fourth quarter revenues to $321.1 million, with a net income of $16.4 million or $0.64 per diluted share [1][3][6] Financial Performance - Fourth quarter revenues increased by 5% compared to $304.8 million in the same quarter of 2024 [3] - Total gross billings for the fourth quarter rose 6% to $2.40 billion from $2.25 billion year-over-year, driven by growth in professional employer services [4] - Net income for the fourth quarter was $16.4 million, slightly down from $16.8 million in the previous year, while diluted earnings per share increased by 2% to $0.64 [6] - For the full year 2025, revenues increased by 8% to $1.24 billion compared to $1.14 billion in 2024, with total gross billings up 9% to $9.04 billion [7][9] Operational Metrics - Average worksite employees (WSEs) increased by 5% in the fourth quarter and by 7% for the full year [9] - Workers' compensation expense as a percentage of gross billings remained stable at 2.3% for both the fourth quarter of 2025 and 2024, benefiting from lower costs [5][10] Capital Allocation - The company repurchased $17 million of stock in the fourth quarter, with approximately $75 million remaining under the stock repurchase program [12] - BBSI paid $2.0 million in dividends during the quarter, with a confirmed quarterly cash dividend of $0.08 per share [13] Liquidity Position - As of December 31, 2025, unrestricted cash and investments totaled $157.2 million, an increase from $121.9 million at the end of 2024, with the company remaining debt-free [11] Future Outlook - For 2026, BBSI anticipates gross billings growth of 3% to 5% and an increase in average WSEs of 2% to 4% [16]

Financial Data and Key Metrics Changes - In 2025, the company achieved a record revenue of $3 billion, representing a 13% increase from 2024 [16] - Adjusted net income for 2025 was $39 million, a 49% increase year-over-year [4] - Base revenue increased by 18% year-over-year, while base gross profit rose by 35% [4][17] - The gross profit margin for 2025 was reported at 8.3%, up from 6.9% in the previous year [17] Business Line Data and Key Metrics Changes - U.S. Gas revenue was $1.3 billion, a 5% increase compared to 2024, with a gross profit margin of 5.4% [18] - Canadian operations revenue was CAD 247 million, up 25% over 2024, with a gross profit margin of 18.6% [18] - Union Electric base revenue reached $800 million, a 21% increase year-over-year, with a base gross profit margin of 8.7% [19] - Non-Union Electric segment had base revenue of $569 million, a 51% increase over 2024, with a base gross profit margin of 8.5% [20] Market Data and Key Metrics Changes - The company maintained a 100% MSA renewal rate and secured over $4.5 billion in bookings, with a book-to-bill ratio of 1.5 times [5][8] - The year-end backlog was approximately $5.9 billion, an increase of 59% from the previous year [10] - The opportunity pipeline includes about 580 bid opportunities valued at $6.7 billion [9] Company Strategy and Development Direction - The company aims to achieve a book-to-bill ratio of 1.1 to 1.2 times for 2026, with a focus on securing new customers and expanding existing scopes of work [8] - The strategy includes addressing seasonality in the gas business and improving fleet efficiency [12][20] - The company is focused on capital efficiency and plans to invest $150 million to $180 million in fleet assets for 2026 [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong market backdrop and the company's ability to deliver growth while maintaining a low-risk profile [24] - The company anticipates continued strong bookings due to multi-year tailwinds within its end markets [7] - Management highlighted the importance of operational excellence and customer service in maintaining its reputation [26] Other Important Information - The company completed the acquisition of Connect Atlantic Utility Services, enhancing its Canadian electric service platform [13] - The net debt to adjusted EBITDA ratio improved to 2.5x, down from 3.6x at year-end 2024 [21] Q&A Session Summary Question: How much of the storm revenue was realized in the January storm? - Management indicated that the storm impact thus far has been minor and in line with last year [28][31] Question: Can you clarify the gross margin expectations in guidance? - Management stated that the gross profit margin would be largely in line with the previous year, with slight improvements expected [32] Question: What are the expectations for margin improvement in the gas segment? - Management expressed confidence in narrowing the gap in seasonality and improving margins through various initiatives [36][38] Question: What is the status of the data center pipeline? - Management confirmed that the win rates have improved and that there are significant opportunities in the data center sector, with $1.3 billion currently tendered [44][94] Question: What initiatives were implemented to drive growth in 2025? - Key changes included establishing a more effective sales pipeline and improving capital efficiency [50][52] Question: What are the plans for tuck-in acquisitions? - Management indicated a focus on geographic presence in the Midwest and electrical transmission for potential acquisitions [90] Question: How is the company addressing working capital to improve cash flow? - Management is focused on reducing Days Sales Outstanding (DSO) and improving billing and collection processes [73]

Core Insights - Establishment Labs reported a strong fourth quarter and full-year 2025, driven by rapid growth in its U.S. Motiva breast implant business and improving profitability metrics [5][8] Financial Performance - The company reported a fourth-quarter net loss from operations of $3.9 million, down 79% from Q4 2024, and adjusted EBITDA of positive $5.5 million, compared to negative $13.1 million in the year-ago quarter [1] - Fourth-quarter revenue was $64.6 million, up 45.2% versus Q4 2024, with full-year 2025 revenue at $211.1 million, an increase of 27.2% over 2024 [4][8] - Gross margin for Q4 was 70.5%, up 200 basis points year over year, with full-year gross margin up 330 basis points versus 2024 [2][7] Market Performance - In the U.S., Motiva revenue was $17.3 million in Q4 and $45.6 million for 2025, with the company exiting 2025 with approximately 20% augmentation market share [3][8] - The company has onboarded over 1,500 U.S. accounts since the late-2024 launch, with strong surgeon interest in Motiva [13] Growth Drivers - The minimally invasive Preserve platform is gaining traction, targeting over 200 trained U.S. surgeons and expected to generate more than $30 million in demand in 2026 [6][16] - Management plans to expand the U.S. sales force by up to 15 representatives in 2026, focusing on experienced industry veterans [14] Future Guidance - For 2026, Establishment Labs guided revenue to $264 million to $266 million, representing 25.1% to 26.0% growth, with expectations for gross margin expansion of 200 to 300 basis points [10] - The company anticipates reaching a first positive cash flow quarter in 2026, with full-year cash flow positivity expected in 2027 [9][19] Product Development - The company submitted Motiva implants to the FDA in December 2025 for primary and revision breast reconstruction, which could effectively double its U.S. total addressable market [17] - Management expressed confidence in obtaining FDA approval for small sizes in the first half of 2026 and mentioned additional pipeline programs for future U.S. introduction [18]

Core Insights - Cemtrex, Inc. reported a 17% increase in revenues for Q1 2026, reaching $16.1 million compared to $13.7 million in the prior year [10] - The company experienced an operating loss of $2.8 million, which is an increase from the $2.3 million loss in the same quarter last year, primarily due to lower gross margins in the Security segment and one-time expenses [4][11] - The Industrial segment achieved a record revenue of $10.6 million, reflecting a 28% increase driven by operational discipline and growing demand [6][10] Financial Performance - Revenues for Q1 2026 increased to $16.1 million from $13.7 million in the prior year, with the Industrial segment contributing $10.6 million, up from $8.3 million [10] - Security segment revenue saw a modest increase of 1%, reaching $5.5 million compared to $5.4 million in the previous year [10] - Cash and cash equivalents surged by 312% to $20.5 million, up from $5 million in the prior year [10] Management Actions - The company implemented pricing adjustments and reduced overhead costs by approximately $2.5 to $3.0 million on an annualized basis to address gross margin compression in the Security segment [5] - Cemtrex completed acquisitions of Invocon and Richland Industries, which are expected to enhance its operational footprint and earnings base starting in Q2 [7] - The management aims to restore segment margins, expand operating income, and strengthen cash flow generation throughout fiscal 2026 [8] Strategic Focus - The company is focused on disciplined execution and capital allocation to build a diversified platform for durable operating income [8] - There is an ongoing commitment to pursue acquisitions that align with the criteria for sustainable margins and cash generation [8] - The early adoption of the NEXT camera line is expected to contribute positively to the Security segment's performance [5]

Core Insights - Wix and Intuit have expanded their partnership to integrate QuickBooks with Wix, providing a unified platform for small businesses to manage sales, finances, and operations alongside their online presence [1][4] - The integration allows millions of Wix users to access QuickBooks Online, offering insights into profitability, cash flow, and tax liabilities, while automating accounting operations [2][4] - QuickBooks customers can create tailored Wix websites with pre-filled business information, benefiting from Wix's AI-powered tools and features for SEO and mobile optimization [3][4] Company Overview - Wix.com Ltd. is a leading global platform founded in 2006, enabling users to create and manage a complete digital presence with advanced AI, flexible web design, and robust business solutions [5] - Intuit Inc. is a global financial technology platform serving approximately 100 million customers worldwide with products like TurboTax, Credit Karma, QuickBooks, and Mailchimp [7]

Core Insights - Labcorp reported strong financial performance for Q4 2025 and the full year, with revenue growth of over 7% and double-digit adjusted EPS growth, driven by its Diagnostics and Central Laboratory businesses [1][2] - The company provided guidance for 2026, projecting revenue between $14.61 billion and $14.79 billion, adjusted EPS between $17.55 and $18.25, and free cash flow of $1.24 billion to $1.36 billion [1][2] Financial Performance - Q4 2025 revenue was $3.52 billion, a 5.6% increase from Q4 2024's $3.33 billion; full-year revenue reached $13.95 billion, up 7.2% from $13.01 billion [1][2] - Adjusted EPS for Q4 was $4.07, compared to $3.45 in Q4 2024; full-year adjusted EPS was $16.44, up from $14.57 [1][2] - Free cash flow for Q4 was $490.3 million, down from $665.1 million in Q4 2024; full-year free cash flow increased to $1.21 billion from $1.10 billion [1][2] Strategic Developments - Labcorp completed several acquisitions, including assets from Empire City Laboratories, Incyte Diagnostics, and Community Health Systems, enhancing its service offerings [1][2] - The company announced plans to build a new 500,000 square foot Central Laboratory facility in Indiana, expected to begin construction in late 2026 [1][2] - Labcorp launched new consumer-initiated tests and expanded access to molecular residual disease testing for various cancers, as well as the first FDA-cleared blood test for Alzheimer's disease [1][2] Capital Allocation - In 2025, Labcorp invested $582 million in acquisitions, paid $240.7 million in dividends, and repurchased $450 million of its stock [1][2] - The company reported a cash and cash equivalents balance of $532.3 million and total debt of $5.58 billion at the end of Q4 2025 [1][2] Segment Performance - The Diagnostics Laboratories segment generated $2.73 billion in revenue for Q4 2025, a 5.5% increase from Q4 2024; adjusted operating income was $419.2 million, with a margin of 15.4% [2][4] - The Biopharma Laboratory Services segment reported $793 million in revenue for Q4 2025, a 3.4% increase, with adjusted operating income of $136.1 million and a margin of 17.2% [2][4]

FOURTH QUARTER AND FISCAL YEAR 2025 Earnings Conference Call Presentation FEBRUARY 11, 2025 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs, and assumptions, and are not guarantees of future performance. Fo ...

I N V E S T O R P R E S E N T A T I O N PRIVATE & CONFIDENTIAL DISCLAIMER This presentation contains forward-looking statements, that reflect current views of Red Rock Resorts, Inc. (the "Company") with respect to, among other things, our operations and financial performance, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implie ...